Welcome to our dedicated page for Bridgebio Pharma SEC filings (Ticker: BBIO), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The BridgeBio Pharma, Inc. (NASDAQ: BBIO) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. BridgeBio is a biopharmaceutical company focused on medicines for genetic diseases, and its filings give detailed insight into clinical milestones, financial condition, capital structure, and corporate governance.
Current reports on Form 8-K are a key source of information for BBIO. The company uses 8-K filings to report material events such as positive Phase 3 topline results for encaleret in autosomal dominant hypocalcemia type 1 and for BBP-418 in LGMD2I/R9, quarterly business updates and financial results, and significant agreements like royalty interest purchase and sale arrangements tied to acoramidis royalties in Europe. 8-Ks also describe shareholder votes on amendments to the certificate of incorporation, stock incentive plans, and other governance matters.
Investors can also review filings that discuss BridgeBio’s financing activities, including proposed offerings of convertible senior notes and the terms, ranking, and convertibility features of such instruments, as well as transactions that monetize future royalty streams. These documents help explain how the company funds commercialization of Attruby (acoramidis) and its broader development pipeline.
On Stock Titan, BBIO filings are updated as new documents are posted to EDGAR. AI-powered summaries highlight the main points of long forms such as 8-Ks, so readers can quickly see why a filing was made, what agreements or results were disclosed, and how it may relate to BridgeBio’s clinical programs, ATTR-CM franchise, or capital structure. Users can drill down into individual filings for full legal and financial detail, including exhibits referenced in the company’s reports.
BridgeBio Pharma (BBIO) Chief Executive Officer and director Kumar Haldea reported routine equity activity on a Form 4 dated 11/16/2025. Several blocks of restricted stock units (RSUs) were converted into common stock as they vested, and a portion of the resulting shares was withheld to cover taxes.
Following these transactions, Haldea directly owns 254,932 shares of BridgeBio common stock. He also reports indirect beneficial ownership of 795,686 shares through the Kumar Haldea Family Irrevocable Trust and 4,598,447 shares through the Kumar Haldea Revocable Trust, where he is a co‑trustee and disclaims beneficial ownership beyond any pecuniary interest. The RSU awards vest quarterly over time as long as he continues serving the company, and the RSUs carry no expiration date.
BridgeBio Pharma, Inc. (BBIO) President and CFO reported stock transactions involving company common shares. On 11/16/2025, 21,317 shares were withheld to cover taxes upon vesting of 38,547 restricted stock units. On 11/17/2025, he sold 9,978 shares at a weighted average price of $66.1923 and 6,956 shares at a weighted average price of $66.8398, with sales executed under a pre-arranged Rule 10b5-1 trading plan adopted on March 31, 2025. Following these transactions, he beneficially owns 382,830 BridgeBio common shares directly.
BridgeBio Pharma, Inc. (BBIO) reported an insider equity transaction by its Chief Accounting Officer on a Form 4. On 11/16/2025, the officer had 4,781 shares of common stock withheld, coded as transaction type "F," at a price of $66.39 per share. This withholding was used to cover tax obligations tied to the vesting of 9,410 shares of common stock underlying restricted stock units.
After this tax withholding, the reporting person beneficially owns 132,297 shares of BridgeBio Pharma common stock in direct ownership. The filing notes that the transaction relates to routine equity compensation vesting and associated tax settlement, rather than an open-market purchase or sale.
BridgeBio Pharma (BBIO) insider filed a Form 4 reporting open‑market sales totaling 80,000 shares of common stock on 11/06/2025 and 11/07/2025, executed under a Rule 10b5-1 trading plan adopted on March 31, 2025.
Sales were made through trusts where the reporting person is a co‑trustee at weighted average prices within disclosed ranges, with individual trades priced from $60.57 to $64.39 per share. Following these transactions, beneficial holdings reported include 4,598,447 shares (Revocable Trust), 795,686 shares (Family Irrevocable Trust), and 223,090 shares held directly.
BridgeBio Pharma (BBIO) disclosed an insider transaction by a director on 11/06/2025. The director exercised 61,031 stock options at $34.65 per share (code M), receiving shares that same day, and then sold 61,031 shares at a $63.7217 weighted average, within a $63.70–$63.88 range.
Following these trades, the director beneficially owned 16,991 common shares directly and 30,523 options remaining, which expire on 02/11/2030. The option grant vested in three annual installments from February 12, 2020 to February 12, 2023.
BridgeBio Pharma (BBIO): Director insider sales reported. On 10/29/2025, a director reported multiple open‑market sales by the Francis P. McCormick Rev Trust U/A DTD 1/27/2017 under a Rule 10b5‑1 plan adopted on August 28, 2024. Transactions included blocks of 111,755 and 43,393 shares, among others, at weighted average prices ranging from $65.4764 to $69.2358. Following the reported sales, 679,979 shares were beneficially owned indirectly by the trust.
BridgeBio Pharma (BBIO): Director transaction reported. A director executed a Rule 10b5-1 planned sale of 1,641 shares of common stock on 10/27/2025 at $65 per share. Following the sale, reported beneficial ownership stands at 878,338 shares held indirectly by the Francis P. McCormick Rev Trust U/A DTD 1/27/2017 and 83,275 shares held directly. The 10b5-1 plan was adopted on August 28, 2024.
BridgeBio Pharma (BBIO) reported Q3 2025 results as it scales commercialization of acoramidis (Attruby/Beyonttra). Total revenues were $120.7 million, driven by net product revenue $108.1 million, plus license and services revenue of $8.3 million and royalty revenue of $4.3 million. Loss from operations was $145.2 million. Net loss attributable to common stockholders was $182.7 million (basic and diluted net loss per share $0.95).
Operating expenses reflected launch build-out: research and development was $112.9 million, selling, general and administrative was $137.6 million, and restructuring, impairment and related charges were $8.8 million. Cash and cash equivalents were $642.9 million as of September 30, 2025. The balance sheet shows 2031 Notes, net, of $564.1 million, 2029 Notes, net, of $740.4 million, and 2027 Notes, net, of $546.5 million. Deferred royalty obligations, net, were $836.1 million.
Year-to-date, total revenues were $347.9 million with product revenue of $216.4 million. U.S. accounted for 89.6% of Q3 revenues. The company notes approvals for acoramidis across the U.S., EU, Japan and the UK supporting the commercial ramp.
BridgeBio Pharma, Inc. reported that it issued a press release titled “BridgeBio Reports Positive Phase 3 Topline Results for Encaleret in Patients with Autosomal Dominant Hypocalcemia Type 1.” The disclosure was made in connection with a current report and the press release is attached as Exhibit 99.1.
The company’s common stock trades on the Nasdaq Global Select Market under the symbol BBIO. The report is dated October 29, 2025 and was signed by the President and Chief Financial Officer. Investors can refer to Exhibit 99.1 for the full press release text.
BridgeBio Pharma, Inc. furnished a press release reporting recent business updates and financial results for the third quarter ended September 30, 2025. The release was provided as Exhibit 99.1 to an Item 2.02 Form 8-K dated October 29, 2025. The company noted that the information in Item 2.02, including Exhibit 99.1, is being furnished and not filed under the Exchange Act.
FAQ
What is the current stock price of Bridgebio Pharma (BBIO)?
What is the market cap of Bridgebio Pharma (BBIO)?
